Ranbaxy acquires Terapia for $324 million

By Lisa Kerner

Erie, Pa., March 29 - Ranbaxy Laboratories Ltd. said it has signed a definitive agreement with Terapia SA of Romania to acquire Terapia for $324 million.

Ranbaxy gains access to the independent generic pharmaceutical company's 157 marketing authorizations with a focus on the cardiovascular system, central nervous system and musculoskeletal therapeutic segments.

Additionally, Ranbaxy can use Terapia's two manufacturing sites producing tablets, capsules, sterile ampoules and liquids.

"Terapia represents exceptional value for our stakeholders," chief executive officer and managing director Malvinder Mohan Singh said in a company news release.

"Within the Ranbaxy fold, it unleashes multiple synergies of product development, product flow, low cost manufacturing, proximity and access to high growth markets, in country presence and sound fundamentals while being EPS accretive to the group immediately."

Ranbaxy is a generic pharmaceutical company based in Gurgaon, India

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.